KR100850331B1 - 이온화 방사선 독성으로부터 세포 및 조직을 보호하는데 사용되는 약학적 조성물 - Google Patents

이온화 방사선 독성으로부터 세포 및 조직을 보호하는데 사용되는 약학적 조성물 Download PDF

Info

Publication number
KR100850331B1
KR100850331B1 KR1020037011357A KR20037011357A KR100850331B1 KR 100850331 B1 KR100850331 B1 KR 100850331B1 KR 1020037011357 A KR1020037011357 A KR 1020037011357A KR 20037011357 A KR20037011357 A KR 20037011357A KR 100850331 B1 KR100850331 B1 KR 100850331B1
Authority
KR
South Korea
Prior art keywords
radiation
pharmaceutical composition
ionizing radiation
cells
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020037011357A
Other languages
English (en)
Korean (ko)
Other versions
KR20030086596A (ko
Inventor
레디이.프렘쿠마
레디엠.브이.라마나
코센자스테판씨.
헬슨로렌스
Original Assignee
템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
온코노바 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션, 온코노바 테라퓨틱스, 인코포레이티드 filed Critical 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션
Publication of KR20030086596A publication Critical patent/KR20030086596A/ko
Application granted granted Critical
Publication of KR100850331B1 publication Critical patent/KR100850331B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020037011357A 2001-02-28 2002-02-28 이온화 방사선 독성으로부터 세포 및 조직을 보호하는데 사용되는 약학적 조성물 Expired - Lifetime KR100850331B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27199001P 2001-02-28 2001-02-28
US60/271,990 2001-02-28
PCT/US2002/006107 WO2002069892A2 (en) 2001-02-28 2002-02-28 METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES

Publications (2)

Publication Number Publication Date
KR20030086596A KR20030086596A (ko) 2003-11-10
KR100850331B1 true KR100850331B1 (ko) 2008-08-04

Family

ID=23037934

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037011357A Expired - Lifetime KR100850331B1 (ko) 2001-02-28 2002-02-28 이온화 방사선 독성으로부터 세포 및 조직을 보호하는데 사용되는 약학적 조성물

Country Status (10)

Country Link
US (1) US6667346B2 (enExample)
EP (1) EP1370253B8 (enExample)
JP (1) JP4302986B2 (enExample)
KR (1) KR100850331B1 (enExample)
AT (1) ATE406881T1 (enExample)
AU (1) AU2002305942B2 (enExample)
CA (1) CA2439288C (enExample)
DE (1) DE60228692D1 (enExample)
IL (2) IL157541A0 (enExample)
WO (1) WO2002069892A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424884C (en) 2000-10-05 2009-12-15 E. Premkumar Reddy Substituted (e)-styryl benzylsulfones for treating proliferative disorders
IL163608A0 (en) * 2002-02-28 2005-12-18 Univ Temple Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
NZ535232A (en) * 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
AU2004289281C1 (en) * 2003-11-14 2011-12-08 Onconova Therapeutics, Inc. Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders
WO2005053682A2 (en) * 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
AU2005222947B2 (en) * 2004-03-16 2010-12-23 Onconova Therapeutics Inc. Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
US8058313B2 (en) 2004-06-24 2011-11-15 Temple University—Of the Commonwealth System of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
AU2005265412B2 (en) * 2004-07-19 2010-09-02 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones
US7537572B2 (en) 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
US20090306207A1 (en) * 2005-01-05 2009-12-10 Reddy M V Ramana Treatment of Drug-Resistant Proliferative Disorders
US8143453B2 (en) * 2005-02-25 2012-03-27 Temple University—Of the Commonwealth System of Higher Education Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
CA2617147C (en) * 2005-07-29 2014-01-21 Onconova Therapeutics, Inc. Formulation of radioprotective .alpha.,.beta. unsaturated aryl sulfones
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
JP2007302640A (ja) * 2006-05-15 2007-11-22 Natl Inst Of Radiological Sciences 抗放射線被ばく障害剤
JP5275985B2 (ja) * 2006-07-28 2013-08-28 オンコノバ・セラピューティックス・インコーポレーテッド 放射線保護α，β不飽和アリールスルホン類の処方
US8664272B2 (en) 2006-08-30 2014-03-04 Temple University—Of the Commonwealth System of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
CA2663375A1 (en) * 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
EP2091527B1 (en) * 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
AU2009310352A1 (en) * 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
WO2010039997A2 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
JP5734869B2 (ja) * 2008-12-16 2015-06-17 オンコノバ・セラピューティックス・インコーポレーテッド ヒトにおける細胞毒性物質の有害作用に対する治療レジメンの有効性を決定する方法
EP3025724B1 (en) 2009-05-13 2018-07-11 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
EA022360B1 (ru) * 2010-03-24 2015-12-30 Онконова Терапьютикс, Инк. Композиции и способы для профилактики и лечения ран
CA2792913C (en) * 2010-03-26 2020-01-21 Onconova Therapeutics, Inc. Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
CA2885217C (en) 2012-09-20 2019-10-08 Temple University - Of The Commonwealth System Of Higher Education Substituted alkyl diaryl derivatives, methods of preparation and uses
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
JP6430483B2 (ja) 2013-03-15 2018-11-28 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法の間の正常細胞の一時的な保護
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
US10195466B2 (en) * 2014-01-06 2019-02-05 Hackensack University Medical Center Method for treating skin cancer using radiation therapy
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
US10383831B2 (en) 2015-08-03 2019-08-20 Temple University—Of the Commonwealth System of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
JP7324930B2 (ja) * 2019-07-18 2023-08-10 フアシアシェンシェン ファーマシューティカル ベイジン カンパニー リミテッド カルバメート置換スチリルスルホン類化合物及びその製造方法ならびにその使用
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6359013B1 (en) 1997-10-03 2002-03-19 Temple University-Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
US20020055530A1 (en) * 2000-04-06 2002-05-09 Neuberger Timothy J. Compositions and methods for promoting tissue regeneration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201154B1 (en) * 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
WO2000059494A1 (en) * 1999-04-02 2000-10-12 Temple University- Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
WO2000059495A1 (en) * 1999-04-02 2000-10-12 Temple University - Of The Commonwealth System Of Higher Education (e)-styryl sulfone anticancer agents
IL149064A0 (en) * 1999-10-12 2002-11-10 Univ Temple Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
US6486210B2 (en) 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
DK1379508T3 (da) * 2001-02-28 2011-01-03 Univ Temple N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6359013B1 (en) 1997-10-03 2002-03-19 Temple University-Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
US20020055530A1 (en) * 2000-04-06 2002-05-09 Neuberger Timothy J. Compositions and methods for promoting tissue regeneration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Org. Chem, 51, 5235-5240(1986.)

Also Published As

Publication number Publication date
CA2439288A1 (en) 2002-09-12
IL157541A0 (en) 2004-03-28
US6667346B2 (en) 2003-12-23
EP1370253B8 (en) 2008-11-26
WO2002069892A2 (en) 2002-09-12
WO2002069892A3 (en) 2002-11-07
US20030060505A1 (en) 2003-03-27
CA2439288C (en) 2011-08-09
KR20030086596A (ko) 2003-11-10
DE60228692D1 (de) 2008-10-16
AU2002305942B2 (en) 2006-10-26
JP4302986B2 (ja) 2009-07-29
IL157541A (en) 2010-05-31
JP2004525908A (ja) 2004-08-26
EP1370253B1 (en) 2008-09-03
EP1370253A4 (en) 2005-08-17
ATE406881T1 (de) 2008-09-15
EP1370253A2 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
KR20030086596A (ko) α,β불포화아릴 술폰을 이용한 이온화 방사선독성으로부터의 세포 및 조직 보호방법
AU2002305942A1 (en) Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones
JP4171656B2 (ja) Ｎ−（アリール）−２−アリールエテンスルホンアミド及びその製薬用途
NO20051108L (no) Cytotoksiske midler som inneholder nye virksomme taksaner og terapeutisk anvendelse av disse
US6767926B1 (en) Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
JP2009541222A (ja) 核、日光、および他の放射線誘発の組織損傷の予防
CN102600200A (zh) 用于预防和治疗粘膜炎及体重减轻的组合物和方法
Floersheim et al. Protection against ionising radiation and synergism with thiols by zinc aspartate
JP5196787B2 (ja) 増殖性疾患を治療するためのα，β−不飽和スルホキシド
EP1223923B1 (en) Unsaturated aryl sulfones for protecting normal cells from cytotoxicity of chemotherapeutic agents
AU2011232341B2 (en) Improved stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfone
PT98866A (pt) Metodo de inibicao de geracao de superoxido, utilizando tioeteracidos fenolicos
JP5553306B2 (ja) 放射線障害防護剤
Patel et al. Overcoming Melphalan Resistance by Targeting Crucial DNA Repair Pathways in Multiple Myeloma
KR101916283B1 (ko) 암에 대한 방사선 치료 증진용 약학적 조성물
WO2022016231A1 (en) Methods of treatment
Hovdenak Acute radiation proctitis. A clinical, histopathological and histochemical study

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030828

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071224

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20080514

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080729

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080730

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110713

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20120710

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130719

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130719

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140710

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140710

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20150708

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150708

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20160714

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20160714

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20170714

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20170714

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20180713

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20180713

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20200716

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20210715

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20220831

Termination category: Expiration of duration